CeriBell (NASDAQ:CBLL) Director Sells $43,786.88 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 2,207 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total value of $43,786.88. Following the transaction, the director directly owned 23,022 shares in the company, valued at approximately $456,756.48. The trade was a 8.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

CeriBell Price Performance

Shares of CBLL stock opened at $19.55 on Friday. The stock’s fifty day moving average price is $18.78 and its 200 day moving average price is $19.72. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33. The company has a market cap of $741.79 million, a price-to-earnings ratio of -11.99 and a beta of 0.77. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million during the quarter, compared to analysts’ expectations of $26.09 million. On average, research analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CBLL has been the topic of several research analyst reports. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Canaccord Genuity Group lowered their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Royce & Associates LP acquired a new position in CeriBell in the 4th quarter worth approximately $11,695,000. JPMorgan Chase & Co. lifted its stake in CeriBell by 8.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after acquiring an additional 31,177 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CeriBell during the 3rd quarter valued at approximately $33,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of CeriBell by 15.3% in the 1st quarter. Bank of America Corp DE now owns 319,837 shares of the company’s stock valued at $5,863,000 after acquiring an additional 42,340 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.